Trust Point Inc. Has $786,000 Holdings in Danaher Co. (NYSE:DHR)

Trust Point Inc. raised its position in Danaher Co. (NYSE:DHR) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,826 shares of the conglomerate’s stock after buying an additional 61 shares during the period. Trust Point Inc.’s holdings in Danaher were worth $786,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Vanguard Group Inc. boosted its position in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Swedbank AB acquired a new position in Danaher during the first quarter valued at approximately $676,545,000. TD Asset Management Inc increased its position in shares of Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares in the last quarter. Finally, Castle Hook Partners LP acquired a new stake in Danaher during the 1st quarter worth approximately $98,913,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Leerink Partners increased their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Stephens assumed coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $282.12.

Danaher Stock Up 0.9 %

Shares of DHR opened at $274.33 on Friday. The firm has a market cap of $203.19 billion, a P/E ratio of 46.50, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm’s 50-day simple moving average is $270.72 and its 200 day simple moving average is $259.92.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the company earned $2.05 earnings per share. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Insider Buying and Selling at Danaher

In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.